Deferred Tax Assets, Valuation Allowance of Acrivon Therapeutics, Inc. from 31 Dec 2021 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Acrivon Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2021 to 31 Dec 2024.
Acrivon Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $56,650,000, a 78% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Acrivon Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$56,650,000	+$24,889,000	+78%	31 Dec 2024	10-K	27 Mar 2025	2024	FY
Q4 2023	$31,761,000	+$17,199,000	+118%	31 Dec 2023	10-K	27 Mar 2025	2024	FY
Q4 2022	$14,562,000	+$8,974,000	+161%	31 Dec 2022	10-K	28 Mar 2024	2023	FY
Q4 2021	$5,588,000			31 Dec 2021	10-K	28 Mar 2023	2022	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.